Introduction {#s1}
============

It has been traditionally thought that physical activity and the processes of learning and memory formation are independent and carried out by different organ systems. However, from an evolutionary perspective, these processes needed to be tightly intertwined to ensure the survival of animal species. Indeed, physical effort usually occurred in response to an imminent danger. Responding to that danger not only required running, but also necessitated better functioning of the brain through increased plasticity in order to adapt to new sources of stress, to learn to avoid dangers or better respond to them, and to map surroundings and learn the locations of hazards ([@bib34]) All of these responses require improved memory.

Physical exercise produces many benefits in the brain that enhance cognitive function, blood flow and resistance to injury. One mechanism to account for the changes in brain plasticity is through the action of growth factors ([@bib10]). A major contributor to the processes of learning and memory formation involves brain derived neurotrophic factor (BDNF) signaling pathways. It has been known for over two decades that physical activity or neuronal activity markedly enhances *Bdnf* gene expression in the brain ([@bib16]; [@bib32]) and that this increase in BDNF protein leads to activation of signaling pathways that result in exercise-dependent enhanced learning and memory formation ([@bib47]). Though these results are widely recognized, it is important to note that very little is known about the molecular mechanisms that link exercise and *Bdnf* expression. Regulation of *Bdnf* expression occurs by many means, but how exercise influences the expression of trophic factors is not understood. In this paper, we are interested in understanding how physical exercise induces *Bdnf* gene expression. This is a significant question, since cognitive ability and synaptic plasticity are influenced by the levels of BDNF ([@bib25]; [@bib35]; [@bib47]) and BDNF signaling is reduced in many neurodegenerative and psychiatric diseases ([@bib4]; [@bib53]).

During development, BDNF is required for the survival of specific neuronal populations and it participates in axonal and dendritic growth and synaptogenesis ([@bib3]; [@bib7]). A number of studies have indicated that decreased levels of BDNF are associated with depression and become enhanced following antidepressant treatment ([@bib12]; [@bib29]). Moreover, exercise frequently leads to an increase in BDNF in the central nervous system to promote improvement in cognitive ability and depressive-like behavior ([@bib27]; [@bib41]). Indeed, physical activity has been shown to have anti-depressant effects and to improve outcomes in animal models and for patients with neurodegenerative diseases such as Parkinson's Disease ([@bib13]) or Alzheimer's disease ([@bib11]). As a result, by understanding the molecular mechanisms by which exercise induces *Bdnf* expression, we aim to harness the therapeutic potential of physical exercise and eventually identify novel therapeutic targets for both psychiatric and neurodegenerative diseases.

In animal models, exercise induces *Bdnf* mRNA expression in multiple brain regions ([@bib10]), most prominently in the hippocampus. BDNF production provides trophic support and increases in synaptogenesis and dendritic and axonal branching and spine turnover. Blocking BDNF signaling attenuates the exercise-induced improvement of spatial learning tasks ([@bib47]), as well as the exercise-induced expression of synaptic proteins ([@bib48]). However, how BDNF is selectively increased after physical activity-dependent changes in the nervous system is not well understood.

One mechanism that has been proposed is that exercise induces *Bdnf* expression through the induction of expression of Fndc5 ([@bib50]), a PGC-1α-dependent myokine. This hypothesis proposes that the FNDC5 protein is cleaved into a small circulating protein called irisin, which has been associated with the browning of fat ([@bib8]). However, there are contradictory reports about whether *Fndc5* is translated and expressed at high levels after exercise and whether irisin is produced and found in blood ([@bib2]; [@bib17]). This raises questions about how and whether a myokine can be responsible for the induction of *Bdnf* gene regulation.

A second hypothesis is that exercise may induce BDNF levels by altering the epigenetic landmarks of the *Bdnf* promoters ([@bib14]; [@bib20]). Because exercise induces metabolic changes and because epigenetics lies at the interfaces between the environment and changes in gene expression, it is conceivable that an endogenous molecule is produced after exercise, which can serve as a metabolite as well as a regulator of *Bdnf* transcription. In this paper, we provide a mechanism demonstrating that exercise induces the accumulation of a ketone body (D-β-hydroxybutyrate or DBHB) in the hippocampus, where it serves both as an energy source and an inhibitor of class I histone deacetylases (HDACs) to specifically induce BDNF expression.

Results {#s2}
=======

Exercise induces Bdnf expression in the hippocampus {#s2-1}
---------------------------------------------------

To assess how exercise enhances *Bdnf* gene expression, we established a voluntary running protocol for mice (4 weeks of age), which has been previously shown to mediate increases in BDNF ([@bib28]). Mice were individually housed in cages and divided into two groups: control and exercise. Each mouse in the exercise group was provided with a running wheel, whereas the control group mice were not. Mice were not forced to run on the wheels, but rather were allowed to run voluntarily. Long term running for up to 30 days was monitored ([Figure 1A](#fig1){ref-type="fig"}) for distance and time. We chose this exercise model because of its voluntary aspect. Stress has been reported to decrease BDNF levels ([@bib31]). For that reason, we avoided any handling or stress induction in the mice. Animals were sacrificed and tissues were collected for analysis. To determine the effects of voluntary running in the hippocampus, we initially focused our study on selective promoters from the *Bdnf* gene, which has a complex structure containing multiple promoters that generate many transcripts with a common coding exon ([@bib36]). Promoter I (pI), a neuronal activity dependent promoter ([@bib43]) and other nearby promoters (pIIA, pIIB, pIV) ([@bib36]), were also assessed for mRNA expression. Our results showed that voluntary exercise for 4 weeks significantly induced BDNF promoter I and II expression in the hippocampus ([Figure 1B](#fig1){ref-type="fig"} and data not shown). Western blot analysis of the hippocampus of animals after voluntary running showed a significant increase of mature BDNF protein levels, as compared to control mice ([Figure 1C and D](#fig1){ref-type="fig"}).10.7554/eLife.15092.003Figure 1.The experimental design and time course of the exercise regime is shown.Exercise induces changes in brain BDNF levels in a voluntary exercise protocol (16). (**A**) Experimental design for the Voluntary exercise model. (**B**) Voluntary exercise for 4 weeks significantly induces *Bdnf* promoter I expression in the hippocampus as measured by real-time RTPCR. The number of animal used for each group (control and exercise) is 10. \*p\<0.05 as measured by unpaired t-test. (**C**) Western blot analysis depicting the increase in mature BDNF protein levels in the hippocampus of exercise animals as compare to wild type. In this representative image, the BDNF levels from 2 control hippocampal lysates and 3 exercise hippocampal lysates are depicted. This experiment was replicated from additional 3 different animals in each group. (**D**) Quantification of the BDNF western blot.**DOI:** [http://dx.doi.org/10.7554/eLife.15092.003](10.7554/eLife.15092.003)

Exercise induces changes in class I HDAC expression and binding to the hippocampal Bdnf promoter {#s2-2}
------------------------------------------------------------------------------------------------

One epigenetic mechanism that has been proposed for inducing *Bdnf* gene expression is histone acetylation ([@bib20]). A number of studies have reported that blocking HDACs enhances memory formation and the expression of synaptic plasticity genes, such as *Creb, Bdnf* and *CamkII* ([@bib14]; [@bib20]). HDACs catalyze the deacetylation of histones and are divided into four classes. Class I (HDAC1, HDAC2, HDAC3 and HDAC8), II and IV are zinc dependent enzymes and are represented by at least 11 different proteins, whereas class III includes the sirtuins ([@bib15]).

We have found that the general class I/IIb HDAC inhibitor, SAHA (vorinostat), a clinically approved anticancer agent and memory enhancer ([@bib14]) and TSA (trichostatin A), a broad-spectrum inhibitor, were effective in inducing *Bdnf* mRNA in primary cortical neuron cultures ([Figure 2A](#fig2){ref-type="fig"}). More specific HDAC inhibitors, such as CI-994 and MS-275, that target class I HDAC members were also capable of elevating *Bdnf* transcripts ([Figure 2B](#fig2){ref-type="fig"}), whereas a non-active analog of CI-994, BRD4097 (manuscript submitted), did not give a response. While these results implicate class I HDAC inhibition in the regulation of synaptic plasticity genes, such as *Bdnf*, it is not clear how exercise is translated into increases in BDNF. Interestingly, we found that exercise reduces *Hdac2* and *Hdac3* mRNA levels, but not *Hdac1* levels in the hippocampus ([Figure 3A](#fig3){ref-type="fig"}). This is consistent with the observation that HDAC2, but not HDAC1, is more important in binding to promoters of activity-related genes ([@bib14]). These results suggest that exercise may modulate *Bdnf* gene expression in the hippocampus by inducing changes to the epigenetic landscape of its promoter. To test this possibility, we performed chromatin immunoprecipitation experiments and showed that the binding of both HDAC2 and HDAC3 to the *Bdnf* promoter in hippocampi of exercise animals was decreased, in comparison to sedentary animals ([Figure 3B](#fig3){ref-type="fig"} and data not shown). Even though some variation was detected in the basal binding of HDAC3 to the *Bdnf* pI promoter, the overall data is consistent with exercise inducing a significant decrease in HDAC3 binding to the *Bdnf* promoter. As a result, these results focused our search for endogenous metabolites that are produced in response to physical activity and that may also act as an epigenetic modulator.10.7554/eLife.15092.004Figure 2.HDAC inhibitors induce *Bdnf* expression.(**A**) Broad spectrum HDAC inhibitors such as TSA (0.67 μM) and SAHA (5 μM) induce coding and pI *Bdnf* expression levels as measured by real-time RTPCR. For the coding promoter, the n number for controls, TSA and SAHA treatments are 6, 5 and 4 respectively. For the pI promoter, the n number for controls, TSA and SAHA treatments are 5, 5 and 4 respectively. Each replicate consisted of primary neurons obtained from different set cultures and treated with fresh dilutions of the compounds. Significance was measured by 1way anova \*\*p\< 0.01.and \*\*\*p\<0.001. (**B**) Treatment with class I HDAC inhibitors such as CI-994 (10 μM) and MS-275 (10 μM) induce coding and pI *Bdnf* levels, whereas the negative control analog for CI-994, BRD4097 does not as measured by real-time RTPCR. For the coding promoter, the n number for controls, CI-994, BRD4097 and MS-275 treatments are 6, 6, 5 and 5 respectively. For the pI promoter, the n number for controls, CI-994, BRD4097 and MS-275 are 5, 6, 5 and 5 respectively. Each replicate consisted of primary neurons obtained from different cultures and treated with fresh dilutions of the compounds. Significance was measured by 1way anova \*\*p\<0.01.and \*\*\*p\<0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.15092.004](10.7554/eLife.15092.004)10.7554/eLife.15092.005Figure 3.Exercise affects *Hdac* expression and binding to the hippocampal BDNF promoter.(**A**) Exercise induces significant decreases in both *Hdac2* and *Hdac3* expression in the hippocampus without affecting *Hdac1* expression as measured by real-time RTPCR. The expression was analyzed from the hippocampi of 4 different control and exercise animals. Unpaired t-tests were used to measure statistical significance \*p\<0.05. (**B**) Exercise induces decreases in HDAC3 binding to the *Bdnf* promoter as measured by chromatin immunoprecipitation followed by real-time RTPCR. The experiment was conducted by using tissues from 7 different control and exercise animals. Unpaired t-tests were used to measure statistical significance \*p\<0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.15092.005](10.7554/eLife.15092.005)

Exercise induces DBHB levels in the hippocampus {#s2-3}
-----------------------------------------------

Exercise is accompanied with increases in energy requirements leading to mitochondrial biogenesis, as well as higher metabolism and oxygen consumption. For example, exercise is often associated with increases in ketone body production. The ketone body D-β-hydroxybutyrate (DBHB) is a major energy metabolite that is increased in the liver after prolonged exercise. DBHB levels are frequently increased after caloric restriction, fasting and ketogenic diets and DBHB is believed to serve as a signaling molecule in response to metabolic changes ([@bib33]). DBHB is synthesized from acetyl-CoA generated from the β-oxidation of fatty acids in the liver. As DBHB production is sensitive to environmental factors, nutritional states and energy levels, it has been hypothesized that ketone bodies may serve as an intermediary to regulate gene expression and chromatin structure. Interestingly, DBHB is transported in the blood stream to the brain where it can serve as an energy source. In addition, DBHB also has been shown to act as a class I HDAC inhibitor in non-neuronal tissues ([@bib42]). To assess the effects of voluntary running, we measured DBHB levels in the hippocampus following exercise. We found that an increase in DBHB levels occurred in mice after exercise, compared to mice not subjected to voluntary running ([Figure 4A](#fig4){ref-type="fig"}).10.7554/eLife.15092.006Figure 4.Exercise increases DBHB levels in the hippocampus.DBHB in turn can induce *Bdnf* expression in vitro in neurons and in vivo in the hippocampus (**A**) Exercise induced DBHB levels in the hippocampus. The number for controls and exercise hippocampi is 10 and 11 respectively. Statistical significance was analyzed by the unpaired t-test \*p\<0.05. DBHB amounts are expressed as millimole per gram of total hippocampal protein (**B**) Overnight treatment of DIV6 primary cortical neurons with 5 mM of DBHB significantly induces coding and pI *Bdnf* expression levels as measured by real-time RTPCR. For both promoters, the n number for controls and DBHB are 4 and 4 respectively. Each replicate consisted of primary neurons obtained from different cultures and treated with fresh dilutions of the compounds. Significance was measured by unpaired t-test \*p\<0.05 and \*\*p\<0.01. (**C**) Three hour treatment of hippocampal slices with DBHB (0.8 mM) induces coding and pI *Bdnf* levels as measured by real-time RTPCR. For both promoters, the n number for controls and DBHB are 5 and 5 respectively. Each replicate consisted of slices obtained from different animals and treated with fresh dilutions of the compounds. Significance was measured by unpaired t-test \*p\<0.05 and \*\*p\<0.01. (**D**) Intraventricular delivery of DBHB (2 mM) significantly induces coding and pI *Bdnf* levels as measured by real-time RTPCR. The n number for controls and DBHB are 3 and 5 respectively. Each replicate consisted of hippocampi from different animals that were subjected to the surgical procedure. Significance was measured by unpaired t-test \*p\<0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.15092.006](10.7554/eLife.15092.006)

DBHB induces BDNF expression {#s2-4}
----------------------------

To evaluate if DBHB had an effect upon *Bdnf* expression, we treated cortical neurons, which represent an abundant source of activity-dependent BDNF. Overnight treatment with DBHB significantly induced the coding and pI-driven *Bdnf* transcripts ([Figure 4B](#fig4){ref-type="fig"}), consistent with the effects of exercise. Treatment of hippocampal slices with DBHB also gave similar results ([Figure 4C](#fig4){ref-type="fig"}). To test the ability of DBHB to induce *Bdnf* in an in vivo setting, we administered exogenous DBHB intraventricularly in mice. Gene expression analysis indicated an increase specifically in *Bdnf* promoter I activity in the hippocampi of mice receiving the intraventricular injection of DBHB as compared to saline injections ([Figure 4D](#fig4){ref-type="fig"}).

DBHB induces BDNF expression through HDAC2/HDAC3 inhibition and Histone H3 acetylation {#s2-5}
--------------------------------------------------------------------------------------

One possible explanation for the effects of exercise is that it induces DBHB accumulation in the hippocampus, which in turn inhibits class I HDACs such as HDAC2 and HDAC3 and leads to induction of *Bdnf* expression. To determine whether DBHB induction of *Bdnf* represents an HDAC-dependent mechanism, we tested whether DBHB treatment affected HDAC2 and HDAC3 occupancy at the *Bdnf* promoters. We find that treatment of primary neurons with DBHB led to decreased HDAC2 and HDAC3 binding to the *Bdnf* promoters ([Figure 5A](#fig5){ref-type="fig"}). This was consistent with an increase in levels of acetylated histone H3 after DBHB treatment ([Figure 5B](#fig5){ref-type="fig"}). Because DBHB is a potent inhibitor of HDAC3 ([@bib42]) and HDAC2 has been previously shown to repress BDNF gene expression ([@bib14]), we focused our attention on HDAC3. Inactivation of HDAC3 either by treating cortical neurons with a HDAC3 selective HDAC inhibitor BRD3308 ([@bib5])[@bib49] ([Figure 5C](#fig5){ref-type="fig"}) or through knockdown using shRNA targeting HDAC3 ([Figure 5D,E,& F,E](#fig5){ref-type="fig"}) both led to increases in *Bdnf* expression. Taken together, these results suggest that inhibition of HDAC2 and HDAC3 in the hippocampus induces *Bdnf* expression.10.7554/eLife.15092.007Figure 5.DBHB induces *Bdnf* expression by inhibiting HDAC2 and HDAC3.(**A**) DBHB (2 mM or 5 mM) treatment decreased the binding of both HDAC2 and HDAC3 on the pI promoter of *Bdnf* as measured by chromatin immunoprecipitation followed by real-time RTPCR. The number of chromatin immunoprecipitations for each HDAC for each treatment were 3 (control), 3 (DBHB 2 mM) and 2 (DBHB 5 mM). Statistical significance was measured by 1way anova \*\*\*\*p\<0.001. (**B**) HISTONE H3 acetylation is increased in neurons upon treatment with different doses of DBHB. Representative blot shown in the figure. (**C**) The HDAC3 selective inhibitor BRD3308 significantly induces *Bdnf* pI expression as measured by real-time RTPCR.. For the coding promoter, the n number for controls and BRD3308 treatments are 6 and 3 respectively. For the pI promoter, the n number for controls and BRD3308 treatments are 5 and 4 respectively. Each replicate consisted of primary neurons obtained from different cultures and treated with fresh dilutions of the compounds. Significance was measured by unpaired t-test \*\*p\<0.01. (**D**)* Hdac3* knockdown is verified by real-time RTPCR. N = 5 represents independent times knockdown was achieved in different primary culture using nucleofection. Significance was measured by unpaired t-test \*\*p\<0.01. (**E**): HDAC3 knockdown is verified by western blotting. (**F**): HDAC3 knockdown significantly induces *Bdnf* coding gene expression as verified by real-time RTPCR. N = 5 and significance was measured by unpaired t-test \*p\<0.05. The *Hdac3* shRNA sequence 2 that significantly reduced HDAC3 protein levels induced *Bdnf* expression.**DOI:** [http://dx.doi.org/10.7554/eLife.15092.007](10.7554/eLife.15092.007)

DBHB links exercise induced metabolic changes in the liver to changes in gene expression in the hippocampus {#s2-6}
-----------------------------------------------------------------------------------------------------------

While brain cells catabolize glucose for energy under normal physiological conditions, ketone bodies are utilized when blood glucose levels decrease, as observed during exercise, fasting or caloric restriction. In order to mimic the increases in DBHB in the brain observed after exercise, we injected mice with 2-deoxy-d-glucose (2-DG), a structural analog of glucose that inhibits glycolysis and increases the brain's capacity to utilize ketone bodies as fuel. 2-DG is transported by glucose transporters into the cell where it binds to, but cannot be phosphorylated by hexokinase, resulting in the inhibition of the first step of glycolysis ([@bib37]). This inhibition leads to the activation of a compensatory mechanism resulting in the production of ketone bodies by the liver. By activating this alternative energy pathway, 2-DG treatment induces DBHB levels in the brain. Interestingly, we found that 2-DG injection, like exercise, also induces both DBHB levels and *Bdnf* expression in the hippocampus to a similar extent ([Figure 6A and B](#fig6){ref-type="fig"}). Interestingly, co treatments of a DBHB transporter inhibitor (AR-C155858) with 2-DG attenuated the 2-DG-induced DBHB levels and *Bdnf* expression. Hence, these findings are consistent with a model in which exercise induces DBHB accumulation in the hippocampus ([Figure 6A and B](#fig6){ref-type="fig"}). DBHB stimulates histone acetylation at the *Bdnf* promoters through reduced HDAC2 and HDAC3 occupancy. This results in an increase in *Bdnf* gene transcription which reflects an epigenetic mechanism after exercise.10.7554/eLife.15092.008Figure 6.DBHB can serve as an exercise factor linking metabolic changes in response to exercise to changes in gene expression in the brain.(**A**) 2-DG treatment known to induce ketone bodies in the brain induces *Bdnf* pI expression in the hippocampus as measured by real-time RTPCR. This effect was blocked by a DBHB transporter inhibitor. N = 10 (Ctrl), N = 9 (2-DG injected) and N = 5 (2-DG and AR-C155858). Significance was measured by unpaired t-test \*p\<0.05. (**B**) 2-DG treatment induced DBHB levels in the hippocampus and this effect is blocked by a DBHB transporter inhibitor.**DOI:** [http://dx.doi.org/10.7554/eLife.15092.008](10.7554/eLife.15092.008)

DBHB induces neurotransmitter release in the hippocampus {#s2-7}
--------------------------------------------------------

To investigate the consequences of an increase of DBHB in the hippocampus, we conducted electrophysiological measurements in hippocampal slices to evaluate DBHB's effects on synaptic transmission. We incubated hippocampal slices with DBHB (0.8 mM) and then carried out field recording of post-synaptic potentials (fEPSPs) in CA1 evoked by stimulating the Schaffer collateral fibers ([@bib51]). Paired pulsed facilitation (PPF) was measured as the ratio of fEPSP slopes in response to two stimuli delivered to the Schaffer collateral inputs. PPF was followed after interstimulus intervals of 20--40 milliseconds. Incubation of hippocampal slices with DBHB (0.8 mM, 3 hrs) increased the fEPSP slope which was blocked by K252a (200 nM). Consistent with these results, DBHB decreased paired pulse ratio in a K252a-dependent manner suggesting a pre-synaptic modulation mediated by TrKB signaling ([Figure 7A and B](#fig7){ref-type="fig"}). The actions of BDNF upon synaptic transmission are known to result in an increase in the frequency of synaptic currents, indicating a presynaptic role of BDNF ([@bib35]). In fact, BDNF rapidly increases spontaneous neurotransmitter release in hippocampal neurons ([@bib18]; [@bib23]), which require TrkB receptors localized at pre-synaptic sites ([@bib22]). These measurements indicated that DBHB treatment enhanced glutamatergic transmission at CA3-CA1 synapses ([Figure 7](#fig7){ref-type="fig"}) and that this DBHB-induced effect was blocked by K252a, a frequently used inhibitor of TrkB receptors in synaptic transmission experiments ([@bib9]; [@bib23]; [@bib44]). K-252a at 200 mM concentration specifically inhibits Trk receptors and not other tyrosine kinase receptors ([@bib6]). Hence the presynaptic enhancement by DBHB is dependent upon the BDNF TrkB receptors. These findings are consistent with an increase of BDNF by DBHB in the hippocampus and furthermore indicate there are additional physiological outcomes mediated by DBHB that involve an increase in neurotransmitter release.10.7554/eLife.15092.009Figure 7.DBHB increases glutamatergic transmission at the CA3-CA1 synapses in a TrkB-sensitive manner.(**A**) Average fEPSP slope in control (6 slices/6 mice), DBHB (6 slices/6 mice), K252a (6 slices/3 mice), and K252a+DBHB (6 slices/3 mice) groups. Two-way repeated measures ANOVA showed significant difference between groups (*F*~3,20 ~= 10.13, p\<0.001). Upper panel shows examples fEPSP traces. (**B**) Average paired pulse ratio in control (6 slices/6 mice), DBHB (6 slices/6 mice), K252a (6 slices/3 mice), and K252a+DBHB (6 slices/3 mice) groups. Two-way repeated measures ANOVA showed significant difference between groups (*F*~3,20 ~= 4.03, p = 0.022).**DOI:** [http://dx.doi.org/10.7554/eLife.15092.009](10.7554/eLife.15092.009)

Discussion {#s3}
==========

These results provide a link between running exercise, the ketone body DBHB and *Bdnf* gene expression. Previous work with DBHB showed it was an effective neuroprotective agent in Huntington's disease ([@bib24]) and Parkinson's disease ([@bib19]; [@bib46]), affecting striatal and dopaminergic neurons, respectively. It is highly conceivable that DBHB might act to increase the levels of BDNF, which can rescue neurons that are vulnerable in Huntington's and Parkinson's disorders ([@bib4]). Indeed, treatment of Alzheimer's disease 3xTgAD mice with 2-DG to induce ketone bodies delayed the progression of bioenergetic deficits in the brain and the associated β-amyloid burden. Similar to our experiments, 2-DG was capable of inducing BDNF in 3xTgAD mice ([@bib52]). Brain is a major source of the secretion of BDNF after exercise ([@bib38]). Moreover, changes in the levels of BNDF have been suggested in the pathophysiology of schizophrenia, addiction and eating disorders ([@bib4]). A number of studies have shown that exercise can also improve depressive-like behavior through increased levels of hippocampal BDNF, which can enhance plasticity and synaptogenesis and reduce neurodegeneration ([@bib1]; [@bib10]; [@bib12]; [@bib25]; [@bib27]; [@bib29]; [@bib41]). Given that histone acetylation in the hippocampus and cortex is associated with effects on learning and memory, the ketone body DBHB serves as a metabolic signal to link environment changes to epigenetic effects on the transcription of neurotrophic factors, such as BDNF.

Ketone bodies are widely distributed from the liver to the heart, muscle and the brain after fasting, dieting and intense exercise. When glucose levels are reduced, ketone bodies, produced in the liver from fatty acids in the form of DBHB and acetoacetate, serve as an energy source. In the brain, the levels of ketone bodies can reach very high levels (1--5 mM) ([@bib30]; [@bib40]). A number of studies have demonstrated neuroprotective effects of ketone bodies in neurodegenerative and neuronal activity, such as under epileptic conditions ([@bib26]).

It is probable there are multiple mechanisms that are involved in the effects of exercise in increasing trophic factor expression. For example, it has been reported that exercise induces *Bdnf* expression through the induction of hippocampal expression of Fndc5 ([@bib50]), a PGC-1α and ERRα -dependent myokine. Once BDNF protein levels increase, TrkB signaling in turn inhibits *Fndc5* expression in a negative feedback mechanism. We found prolonged exercise decreased *Fndc5* expression levels consistent with elevated BDNF protein in the hippocampus ([@bib50]). However, DBHB did not induce *Pgc-1α, Fndc5*, or *Erra* mRNA in primary neurons (data not shown), suggesting that there are alternative ways of affecting BDNF levels. The complexity of the BDNF gene and its alternative promoters and splicing events ([@bib15]) indicates that several regulatory mechanisms must exist to explain its many functions in synaptic transmission and neuronal survival ([@bib35]). Interestingly, exercise induces *Bdnf* expression in the hippocampus and not in all the other regions of the brain. How this specificity is achieved is not clear. One possible explanation suggests that exercise may regulate the levels or functions of ketone body transporters in different regions of the brain. Indeed, acute exercise induces *Mct2* transporter expression in the hippocampus immediately after and up to 10 hr post-exercise. This exercise-induced upregulation of *Mct2* was associated with increases in BDNF and TrkB levels ([@bib45]).

Our finding of an endogenous metabolite, DBHB, which upregulates *Bdnf* transcription in the hippocampus, provides one explanation linking the effects of exercise and peripheral metabolism to changes in epigenetic control and gene expression in the brain. There are multiple links between metabolic changes resulting from exercise and epigenetic modulation. For example, it has been reported that the blood levels of some Kreb's cycle intermediates such as α-ketoglutarate are increased after exercise ([@bib21]). Interestingly, α-ketoglutarate is an essential co-substrate for jumanji histone demethylases as well as for the tet proteins (DNA demethylases). Another molecule that may play a critical role in linking metabolic changes induced by exercise to epigenetic modulation is acetyl CoA which serves as the source of the acetyl group for all acetylation reactions catalyzed in the body including those catalyzed by histone acetyltransferases. Finally, coenzymes such as NAD+, or FAD produced during metabolic reactions are also required by sirtuins and the histone demethylase LSD1, respectively.

In this paper, we provide evidence that an endogenous molecule, DBHB, that crosses the blood brain barrier, is increased by physical exercise to enhance the expression of a fundamental trophic factor in the brain and in turn affect synaptic transmission ([Figure 8](#fig8){ref-type="fig"}). Further studies aiming at identifying molecules that can also serve the dual purpose of an energy fuel and epigenetic modulator will help us accumulate additional members of the "exercise pill". The identification of these molecules is of great interest as many people afflicted with depression or with neurodegenerative diseases are likely to benefit from the ability of exercise to stimulate BDNF through small metabolites, such as DBHB. The involvement of ketone bodies in many other syndromes, such as glucose utilization, diabetes and epilepsy, suggests they represent vital molecules with broad metabolic effects upon chromatin and gene expression.10.7554/eLife.15092.010Figure 8.A proposed model by which exercise induces *Bdnf* expression in the hippocampus.Exercise induces DBHB synthesis in the liver. DBHB is transported through the circulation to peripheral organ including the brain. In the hippocampus, DBHB induces *Bdnf* expression through a mechanism involving HDAC inhibition. This induction in turn mediates exercise's positive effects on memory, cognition and synaptic transmission.**DOI:** [http://dx.doi.org/10.7554/eLife.15092.010](10.7554/eLife.15092.010)

Materials and methods {#s4}
=====================

Exercise paradigm {#s4-1}
-----------------

Male mice were individually housed with food and water ad libitum, lights on: 6 AM and lights off 6 PM. They were divided into 2 groups (Control and Running, n = 10 each); Control mice and running animals were housed with free access to a running wheel. Running distance and time were monitored (Coulborn Instruments). Animals were sacrificed after 30 days and hippocampus and cortex were collected and immediately frozen on dry ice. Animal care and use was in accordance with the guidelines set by the National Institutes of Health and the New York State Department of Health

Cell culture {#s4-2}
------------

Immature primary cortical neurons were obtained from C57BL/6 mice \[embryonic day 17 (E17)\] as previously described ([@bib39]). Mature cortical neurons were maintained in Neurobasal media (Invitrogen) supplemented with MACS NeuroBrew- 21 (Miltenyi Biotec), and Glutamax (Invitrogen).

Cell treatment {#s4-3}
--------------

Primary neurons wereisolated as described above and 0.5 million cells were plated in six well plates. On Day 6, cells were treated with different concentrations of DBHB overnight or HDAC inhibitors for 5 hr. DBHB was prepared as 1 M stock in PBS and used at a final concentration of 5 mM. suberoylanilide hydroxamic acid (SAHA), Acetyldinaline (CI-994), Entinostat (MS-275), BRD3308 and BRD4097 were prepared as 10 mM stocks in DMSO and used at a final concentration of 10 μM. Trichostatin A (TSA) was prepared as a 670 μM stock and used at a final concentration of 0.67 μM.

RNA extraction and Real Time PCR {#s4-4}
--------------------------------

Total RNA was prepared from primary cortical neurons or hippocampi usingthe NucleoSpin RNA II Kit (Clontech) according to the manufacturer's protocol. Real-time PCRs wereperformed using standard PCR protocol. Details of the Primers used are provided below:

Primer sequence (5'-3'): {#s4-5}
------------------------

*Bdnf* coding (Fwd): GCGGCAGATAAAAAGACTGC

*Bdnf* coding (Rev): GCAGCCTTCCTTGGTGTAAC

*Bdnf* Var (Rev): GCCTTCATGCAACCGAAGTA

*Bdnf* Var I (Fwd): CAGGACAGCAAAGCCACAAT

*Gapdh* (Fwd): CTCTCTGCTCCTCCCTGTTC

*Gapdh* (REV): CCGACCTTCACCATTTTGTC

*Hdac3* (Fwd): ATGCCTTCAACGTGGGTGAT

*Hdac3* (Rev): CCTGTGTAACGGGAGCAGAAC

DBHB measurement {#s4-6}
----------------

DBHB levels were measured using a DBHB Assay kit (MAK041, Sigma) according to manufacturer's protocol.

Immunoblot analysis {#s4-7}
-------------------

*To determine HDAC3, acetyl HISTONE H3, and HISTONE H3 protein levels, total cell proteins were prepared by lysing cells in RIPA-B* (1% Triton X-100, 1% SDS, 50 mM Tris-Cl, pH 7.4, 500 mM NaCl and 1 mM EDTA) in the presence of protease inhibitors (Sigma), the proteasome inhibitor MG-132 (Sigma) and phosphatase inhibitors (Sigma) followed by benzonase nuclease (Sigma) digestion for 15 min. Samples were boiled in Laemmlibuffer and electrophoresed under reducing conditions on NuPAGE Novex 4--12% for Bis-Tris Gel polyacrylamidegels (Invitrogen). Proteins were transferred to a nitrocellulose membrane(Bio-Rad) by electroblotting. Nonspecific binding was inhibitedby incubation in Odyssey blocking buffer (LI-COR Biosciences). Antibodies against HISTONE H3 (Cell signaling) and acetylated HISTONE H3 (Millipore), HDAC3 (ab16047, Abcam) and β-ACTIN (AC-74; Sigma-Aldrich) were diluted 1:1000, 1:1000, 1:1000; and 1:10,000, respectively, in odyssey blocking buffer and the membranes were incubated overnight at 4°C. Fluorophore-conjugated Odyssey IRDye-680 or IRDye-800 secondary antibody (LI-COR Biosciences) was used at 1:10,000 dilution followed by incubation for 1 hr at room temperature. Finally, proteins were detected using an Odyssey infrared imaging system (LI-COR Biosciences). To determine BDNF protein levels, total hippocampal proteins were *prepared by homogenizing tissues in* RIPA-B in the presence of protease inhibitors, the proteasome inhibitor MG-132 and phosphatase inhibitors followed by benzonase nuclease digestion for 15 min. Samples (100μg) were boiled in Laemmlibuffer and electrophoresed under reducing conditions on NuPAGE® Novex 12% Bis-Tris Gel polyacrylamidegels. Proteins were transferred to a nitrocellulose membrane(Bio-Rad) by electroblotting. The membranes were washed twice with 1X PBS followed by 30 min incubation with 2.5% glutaraldehyde/PBS. The membranes were washed twice again with PBS and then with TBS-T. Nonspecific binding was inhibitedby incubation in 5% milk/TBS-T followed by incubation with the BDNF antibody (N-20, Santa Cruz) for 2 hr at room temperature. A peroxidase conjugated goat anti-rabbit or anti mouse was used for BDNF or actin detection, respectively. The membranes were detected by chemiluminescence.

Hippocampal slices {#s4-8}
------------------

Animal care and use was in accordance with the guidelines set by the National Institutes of Health and the New York State Department of Health. 5-week old male mice were anesthetized and decapitated. The brain was dissected and placed in 4°C cutting buffer (126 mM sucrose, 5mM KCl, 2 CaCl~2~, 2 mM MgSO~4~, 26 mM NaHCO~3~, 1.25 mM NaH~2~PO~4~, and 10 mM D-glucose, pH 7.4). The hippocampus was dissected and submerged in ice-cold cutting buffer and cut horizontally into 300-μm sections, which were immediately placed in recovery solution {50% cutting solution/ 50% artificial cerebrospinal fluid (ACSF)} and oxygenated (95% CO~2~-5% O~2~) for 20 min. The slices were then transferred in to ACSF oxygenated chambers and treated with DBHB (0.8 mM concentration) for 3 hr after which RNA was extracted for Real-Time RT PCR analysis.

Intraventricular delivery of *DBHB* {#s4-9}
-----------------------------------

All surgeries were performed in accordance to IACUC rules. Mice were anesthetized under isoflurane and placed on a stereotaxic frame (David Kopf instruments, CA). The body temperature of the animals was maintained at 37°C using a homeothermic blanket. DBHB (2 mM and 5 mM; 5 µl) was delivered by a Hamilton syringe at a flow rate of 0.5 µl/min using a nanomite syringe pump (Harvard apparatus, MA). The stereotaxic coordinates relative to bregma were as follows: AP, -0.46 mm; L, -1.20 mm; DV, 2.20 mm. (Paxinos and Watson, 1998). In sham control animals, 5 µl of saline (vehicle) were infused. Proper post-operative care was taken until the animals recovered completely. Mice were sacrificed after 6 hr following the injection and the different brain regions were dissected.

Hdac3 short hairpin RNA knockdown {#s4-10}
---------------------------------

*Hdac3* (NM_010411)

short hairpin RNA (shRNA) clone (TRCN0000039391, 5' CCGGGTGTTGAATATGTCAAGAGTTCTCGAGAACTCTTGACATATTCAACACTTTTTG 3′; Sigma) and Non-Target shRNA Control Vector (Sigma) were introduced into immature primary cortical neurons (E17) using the Amaxa mouse Neuron Nucleofector kit as directed by the manufacturer (Lonza). On Day 6, HDAC3 knockdown was confirmed by Real-time RTPCR and whole-cell lysate Western blots.

Chromatin immunoprecipitation {#s4-11}
-----------------------------

The Ez-Magna ChIP assay kit was used as directed by the manufacturer (Millipore). Briefly, primary cortical cells were crosslinked with 1% formaldehyde at 37°C for 7 min. Cells were then sonicated using the Bioruptor (Diagenode) and immunoprecipitated with primary antibodies (10 µg). The crosslinking was reversed, and the DNA was isolated on the columns provided by the kit. Shearing size was determined to be between 150 and 1000 bp. Real-time PCR was conducted with primers targeted to the BDNF pI promoter (TGATCATCACTCACGACCACG and CAGCCTCTCTGAGCCAGTTACG) and SYBR Green PCR Master mix (Applied Biosystems). Each experiment was conducted at least three times by crosslinking cells from different primary cortical neuron preparations.

2- deoxy-d-glucose injections {#s4-12}
-----------------------------

mice received intraperitoneal injections of 10mg/Kg of 2-DG or saline. They were left to recover for 6 hrs after which the animals were sacrificed and the tissue was harvested.

Electrophysiology {#s4-13}
-----------------

2--4 months old C57BL6 male mice were anesthetized by pentobarbital anesthesia. After decapitation, hippocampi were isolated in ice-cold artificial cerebrospinal fluid (ACSF) containing the following (in mM), NaCl (118), KCl (4.5), glucose (10), NaH~2~PO~4~ (1), CaCl~2~ (2) and MgCl~2~ (2) (aerated by 95%O2/5% CO2, pH adjusted to 7.4 with NaHCO~3~). Hippocampal slices (300 μm) were prepared on a vibratome (Campden Instruments) and maintained at room temperature for 1 hr in a brain slice keeper. Brain slices were incubated in vehicle (0.00007% DMSO), K252a (200 nM), DBHB (0.8 mM) or combination of K252a and DBHB for 3 hrs at room temperature before recording CA1 field excitatory post-synaptic potentials (fEPSPs) in a recording chamber perfused with ACSF at 32°C. fEPSPs were evoked by stimulation of the Schaffer collateral fibers using a concentric bipolar electrode (FHC). Input-output data were generated by plotting fEPSP slope in response to 100, 200, 300, 400 and 500 μA stimulation. Paired pulse ratio was measured as ratio of second fEPSP slope to first EPSP slope at 20, 40, 80, 120 and 160 ms inter-stimulus interval. A response approximately 35% of the maximum evoked response was used for studying paired pulse ratio. Data were acquired using pCLAMP 10 program and MultiClamp 700B amplifier (Molecular Devices). Data analysis was carried out using Clampfit program.

Statistical analysis {#s4-14}
--------------------

unpaired t-test, 1way or 2way ANOVA followed by the Dunnett or Bonferroni post tests respectively were used to measure statistical significance. p\<0.05 was considered to be statistically significant.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Exercise promotes the expression of BDNF through the action of the ketone body Β-hydroxybutyrate\" for consideration by *eLife*. Your article has been favorably evaluated by K VijayRaghavan (Senior editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Sleiman and colleagues describe results from a series of studies linking rises of ketone bodies during exercise and increased BDNF expression in the hippocampus. In particular, they demonstrate that β-hydroxybutyrate (BHB) rise in their exercise paradigm and this leads to increased BDNF. They mimic this rise in vitro by treating hippocampal slices and report an increase in BDNF. Finally, they used ICV injections of BHB to demonstrate that this also could activate BDNF transcription. The proposed mechanism suggests an exercise-induced elevation in circulating levels of BHB inhibits the repressing effects of HDAC2 and 3 on the Bdnf promoter 1. Collectively, the studies are well described and provide interesting results. Indeed, the results will likely be of wide interest in the fields of neuroscience, exercise physiology and metabolic research.

Essential revisions:

Because exercise can induce BDNF expression through BHB-independent mechanisms, the physiological relevance of this pathway is not clear. Studies informing the necessity of this pathway on the beneficial effects of hippocampal BDNF on cognitive function, antidepressant efficacy or synaptic plasticity would strengthen the conclusions of the manuscript.

The Western data presented in [Figure 1C](#fig1){ref-type="fig"} needs to be quantified before reaching the conclusion that BDNF levels are elevated, especially as the samples from exercise animals appear to be over loaded.

The authors made the initial observation that exercise induces BDNF expression driven by both promoters 1 and 2. It is not clear why subsequent experiments only focus on promoter 1.

[Figure 1B](#fig1){ref-type="fig"} convincingly shows that exercise increases hippocampal expression of mRNA for the promoter I BDNF transcript, but the data seemingly indicates that there is no significant effect on the levels of expression detected with primers within the translated region of the transcript, presumably because promoter I does not account for a major fraction of BDNF expression. I think the authors need to discuss this feature of the data. Concern about the issue is heightened by the western blot data in [Figure 1C](#fig1){ref-type="fig"}, where the upregulation of BDNF protein levels is not entirely convincing. (One of 3 replicates for the Exercise condition seems no higher than one of the 2 replicates for the control condition). Densitometric quantification, with normalization against the actin band, might dispel this concern.

Some of the data in [Figure 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"} are compelling. However, the data in 3B, interpreted to indicate that exercise decreases the HDAC3 occupancy of BDNF promoter I, does not provide statistical analysis, and the statistical significance is unclear.

The evidence ([Figure 4](#fig4){ref-type="fig"}) that exercise increases BHB in brain seems quite convincing. However, in the Discussion, the authors cite published evidence that brain BHB levels may reach 1-5 mM, yet they report levels of 10-15 mM (calculated assuming a brain density of 1.0 g/ml), and I found two studies reporting ketogenic diet or alcoholic ketoacidosis producing maximum brain β-hydroxybutyrate levels of 180 and 120 μM (Samala et al., 2011 and Schrieber and Ungar, 1984). The dose of ICV injections of the BHB needs to be justified. Is it known whether these doses affect metabolic function in key peripheral tissues? Does this dose affect other brain regions?
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Author response

Essential revisions:

Because exercise can induce BDNF expression through BHB-independent mechanisms, the physiological relevance of this pathway is not clear. Studies informing the necessity of this pathway on the beneficial effects of hippocampal BDNF on cognitive function, antidepressant efficacy or synaptic plasticity would strengthen the conclusions of the manuscript.

We thank the reviewers for this pertinent comment. In order to address this comment, we have performed two different types of experiments to address the physiological relevance of DBHB.

First, we injected 2- Deoxy- D-glucose (2-DG) alone or in combination with a DBHB transporter inhibitor, AR-C 155858 and assessed both BDNF promoter I expression as well as DBHB levels. DBHB levels increase when there is a switch from glucose to fatty acid metabolism. We have found that glycolytic inhibition by 2-DG induces both BDNF promoter π expression and DBHB levels in the hippocampus, whereas injecting 2-DG along with AR-C155858 attenuated both DBHB levels and the induction of BDNF π expression in the hippocampus ([Figure 6A and B](#fig6){ref-type="fig"}). These results suggest that increased DBHB levels in the hippocampus by physiologically manipulating glucose metabolism can contribute to BDNF promoter 1 induction by HDAC2/3 inhibition. This is important because exercise mediates its positive effects on learning and memory through BDNF expression (Erickson et al., 2011). Our results showing that DBHB accumulation in the hippocampus can affect BDNF expression suggest a role for DBHB in mediating the learning and memory effects through BDNF expression.

In a second physiological approach, we have also found that DBHB induces presynaptic glutamate release, which is dependent upon BDNF/TrkB signalling ([Figure 7A and B](#fig7){ref-type="fig"}). Hippocampal slices were prepared and incubated with DBHB for 3 hr before measurements of CA1 field excitatory post-synaptic potentials (EPSPs) after stimulation of Schaffer collaterals. Pair pulse facilitation (PPF) due to an accumulation of residual Ca^2+^ in the presynaptic terminal was observed and is indicative of enhanced transmitter release. This DBHB induced response could be blocked by treatment with K252a, a frequently used inhibitor of TrkB receptors in synaptic transmission experiments (Chen et al., 2015; Li et al., 1998; Takei et al., 1998). These findings are consistent with an increase of BDNF by DBHB in the hippocampus and furthermore indicate that one physiological outcome of DBHB is an increase in neurotransmitter release through a TrkB dependent mechanism.

Taken together, these results suggest that the production of DBHB is indeed involved in the induction of BDNF expression and that the induced and activated BDNF pathway plays important roles in mediating the effects of DBHB on glutamate release.

The Western data presented in [Figure 1C](#fig1){ref-type="fig"} needs to be quantified before reaching the conclusion that BDNF levels are elevated, especially as the samples from exercise animals appear to be over loaded.

We have quantified the western blot presented in [Figure 1](#fig1){ref-type="fig"} comparing BDNF levels from the hippocampi of control and exercise mice and the quantification is presented as [Figure 1D](#fig1){ref-type="fig"}. The western blots were quantified using image J software. The quantification shows a significant increase in BDNF protein levels in hippocampi of exercise animals as compared to ctrl animals. The significance was assessed by student T-test and p-value\< 0.05. These results are consistent with previously published results showing that exercise induces BDNF levels in the hippocampus using immunofluorescence and Elisa techniques (Cotman and Berchtold, 2002).

The authors made the initial observation that exercise induces BDNF expression driven by both promoters 1 and 2. It is not clear why subsequent experiments only focus on promoter 1.

[Figure 1B](#fig1){ref-type="fig"} convincingly shows that exercise increases hippocampal expression of mRNA for the promoter I BDNF transcript, but the data seemingly indicates that there is no significant effect on the levels of expression detected with primers within the translated region of the transcript, presumably because promoter I does not account for a major fraction of BDNF expression. I think the authors need to discuss this feature of the data. Concern about the issue is heightened by the western blot data in [Figure 1C](#fig1){ref-type="fig"}, where the upregulation of BDNF protein levels is not entirely convincing. (One of 3 replicates for the Exercise condition seems no higher than one of the 2 replicates for the control condition). Densitometric quantification, with normalization against the actin band, might dispel this concern.

We have quantified the western blots and included the quantification in [Figure 1D](#fig1){ref-type="fig"} as mentioned above. Indeed, BDNF protein levels are induced in the hippocampi of exercise animals as compared to control animals. We have found that both promoter 1 and 2 are significantly induced by exercise. Even though the coding exon was not significantly induced, we observe a trend suggesting the increase. This trend is consistent with the western blot quantification data. Indeed, DBHB also induces promoter 2 (Data not shown) as well as the coding fraction ([Figure 4B, C and D](#fig4){ref-type="fig"}). We focused on promoter 1 because previous microarray data (Tong et al., 2001) have detected an increase in promoter 1 in exercise rats as compared to control rats.

Some of the data in [Figure 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"} are compelling. However, the data in 3B, interpreted to indicate that exercise decreases the HDAC3 occupancy of BDNF promoter I, does not provide statistical analysis, and the statistical significance is unclear.

We have increased the n number from 3 to 7 for each group for theexperiment and included statistical data. The results in [Figure 3B](#fig3){ref-type="fig"} suggest that exercise significantly (p\<0.05) decreases HDAC3 binding to the BDNF promoter 1.

The evidence ([Figure 4](#fig4){ref-type="fig"}) that exercise increases BHB in brain seems quite convincing. However, in the Discussion, the authors cite published evidence that brain BHB levels may reach 1-5 mM, yet they report levels of 10-15 mM (calculated assuming a brain density of 1.0 g/ml), and I found two studies reporting ketogenic diet or alcoholic ketoacidosis producing maximum brain β-hydroxybutyrate levels of 180 and 120 μM (Samala et al., 2011 and Schrieber and Ungar, 1984). The dose of ICV injections of the BHB needs to be justified. Is it known whether these doses affect metabolic function in key peripheral tissues? Does this dose affect other brain regions?

The DBHB levels are expressed in mmole/gram. The grams in the denominator refer to the normalization to the total amount of hippocampal protein and not the grams of hippocampal tissue. We have clarified this point in the graph in [Figure 4A](#fig4){ref-type="fig"}. From here, the concentration extrapolations are not accurate. The concentrations obtained, if we consider the volume used for DBHB measurement per the manufacturers' instructions, have an average of 0.9mM (Control) and 1.3mM (Exercise). Therefore, considering our measurements and the observation that exercise modulates HDAC binding to the BDNF promoter, we chose the concentrations for ICV to be close to the measured levels and also close to the concentrations reported to have effects on HDAC inhibition (Shimazu et al., 2013).
